Deep-dive AI research reports on individual stocks, powered by our proprietary signals. Every report carries a direction (Bullish or Bearish) and a conviction level(Strong or Speculative). We track stock performance since each report's publication date — because we believe great analysis should be held accountable.

AllAAOIABUSABVXACADACRVADMAAGIOALMSALMUALTSAPGEARTVASXAUPHAVAVAVPTAXTIBCRXCAICAKECEGCELCCEPCGONCIENCNCCOGTCRCLCTMXCTRIDKNGDUOLFLUTGCTGLWGOOGGPCRHALOHCAHIMSHOODHWMIDYAIRENIVVDKALAKALVKRYSLENZLEVILITELQDALRMRLULULUNRMDGLMESOMIRMMOHMPWRMTCHMUMVSTNBISNKENRIXNUENVAXNXPIOKUROLMAONCONTOORKAOSCRPDFSPHATPOETPRLDPYGRBLXRDDTRIGLRKLBSGHCSPRYSRPTTARSTBPHTHTRVITSHATTMIUNHVEONVORWVEXFORZBIOZLABZYME
BeiGene (soon BeOne Medicines) has achieved GAAP profitability in Q1 2025, driven by strong sales of BRUKINSA (792M,+62171M). The company's strategic redomiciliation to Switzerland and recent patent victory bolster its global oncology position. With a robust pipeline (17 Phase 3 trials) and 4.9B−5.3B revenue guidance, BeiGene presents a compelling investment case. Analysts recommend "Buy" given its growth trajectory and profitability.

Investing in China’s Biotech Rise: BeiGene (ONC) and the Future of BeOne Medicines

2025-06-25Change from report: +40.7%1M: +14.5%3M: +29.2%

BeiGene (soon BeOne Medicines) has achieved GAAP profitability in Q1 2025, driven by strong sales of BRUKINSA (792M,+62171M). The company's strategic redomiciliation to Switzerland and recent patent victory bolster its global oncology position. With a robust pipeline (17 Phase 3 trials) and 4.9B−5.3B revenue guidance, BeiGene presents a compelling investment case. Analysts recommend "Buy" given its growth trajectory and profitability.